phe885
Cell therapyexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 30, 2020 (NCT04318327)
Timeline
Indications
Studied for
Mechanism of action
- BCMAImmunity, passive
BCMA immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05172596 | Phase 2 | Mar 7, 2022 | Novartis |
| NCT04318327 | Phase 1 | Mar 30, 2020 | Novartis |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 2 | 2 | 2 | 2020 |
1 organizations
Page 1 / 1